Clinical Trials Logo

Ischemia clinical trials

View clinical trials related to Ischemia.

Filter by:

NCT ID: NCT01387113 Completed - Ischemic Stroke Clinical Trials

The PERFusion Use in Stroke Evaluation Study

PERFUSE
Start date: May 2011
Phase:
Study type: Observational

This is an open label single center phase II trial, evaluating the utility of 64 slice CT perfusion (CTP) in acute ischemic stroke (AIS) patients. The main aim is to determine which aspects of CTP imaging can aid in expanding the time window for thrombolysis with IV (rt-PA) in AIS patients up to 6 hours after symptom onset.

NCT ID: NCT01386216 Completed - Clinical trials for Critical Limb Ischemia (CLI)

Safety Study of Bone Marrow Cell Concentrate Prepared Using the Magellan System to Treat Critical Limb Ischemia (CLI)

CLI
Start date: April 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety of administration of marrow-derived autologous hematopoietic stem cells (HSC) concentrate and platelet-rich plasma (PRP) gel for the treatment of Critical Limb Ischemia (CLI).

NCT ID: NCT01378468 Active, not recruiting - Clinical trials for First Ischemic Stroke

Prognostic Impact of an Oral Triglyceride Tolerance Test in Patients After Acute Ischemic Stroke

Start date: January 2009
Phase: N/A
Study type: Observational

Non-fasting triglyceride levels are thought to play a role in stroke. The investigators hypothesise that the results of a standardised oral triglyceride tolerance test in the subacute setting (3-7 days) after the first ischaemic stroke are associated with the risk of recurrent stroke within 12 months after the index event.

NCT ID: NCT01378000 Completed - Clinical trials for Acute Cerebral Ischemia

Study on Continuous Intravenous of Unfractionated Heparin (UFH) to Treat Progressive Cerebral Infarction

UHPCI
Start date: October 2009
Phase:
Study type: Observational

A clinical trial to study the effects of dosage, infusion methods and complications of unfractionated heparin (UFH) treating acute progressive cerebral infraction was conducted. In this study, we observed the effects of four UFH treatments on 480 acute progressive cerebral infraction patients during from the 6th and the 72nd hour after the attack. It was concluded that the ultra-slow continuous intravenous infusion of UFH can significantly reduce the neurological deficit score of patients with progressive cerebral infarction, increase the cure rate, decrease the recurrence rate, and improve long-term quality of daily life. It is more effective than the treatment of intravenous infusion of low- molecular- weight UFH at once a day, and the risk of bleeding may not necessarily be increased.

NCT ID: NCT01376609 Not yet recruiting - Ischemic Stroke Clinical Trials

The Correlation Between Outcome and Infarct Growth in Patients With Acute Ischemic Stroke

COIG
Start date: August 2011
Phase: N/A
Study type: Observational

Previous research has shown there wasn't inevitable relationship between mismatch area and infarct growth according to Volumetric-subtraction mismatch volume.The recently published on Stroke paper has proposed Coregistration mismatch to calculate the mismatch to replace ischaemic penumbra, and it reignites hope for clinical application of the PWI/DWI mismatch. But the correlation between the mismatch, calculated by Coregistration mismatch method,and the clinical outcome of the patients with acute ischemic stroke is still unknown. so the investigators plan to conduct a prospective observational cohort study.

NCT ID: NCT01375400 Unknown status - Ischemic Stroke Clinical Trials

Effect of Aspirin at the Acute Phase of Cerebral Ischemic Event.

Aspirin
Start date: December 2010
Phase: N/A
Study type: Interventional

Aspirin is the only anti-platelet medication used at the acute phase of ischemic stroke. The investigators would like to study laboratory effect of the first oral 300 mg dose of aspirin, given at hospital, after an ischemic event. The principal hypothesis is that platelet activity would be able to recover during this day and could lead to ischemic recurrences. Two blood samples are accomplished. The first 2 hours after aspirin intake and the second 23 hours after. Photometric aggregometry are performed with arachidonic acid and collagen induced platelet aggregation, measure of thromboxan B2 levels and reticular platelets count.

NCT ID: NCT01373502 Completed - Stable Angina Clinical Trials

International Randomized Comparison Between DES Limus Carbostent and Taxus DES in the Treatment of De-novo Coronary Lesions

NEXT
Start date: October 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to demonstrate non-inferiority in terms of safety and efficacy of DES Limus Carbostent compared to the Taxus Liberté in treating de-novo atherosclerotic lesions in native coronary arteries.

NCT ID: NCT01363687 Completed - Clinical trials for Kidney Transplantation

The Effect of Remote Postconditioning on Graft Function in Patients Undergoing Living-related Kidney Transplantation

Start date: August 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate whether upper limb ischemic postconditioning can improve renal function and decrease ischemic-reperfusion injury in patients undergoing living donor kidney transplantation.

NCT ID: NCT01357499 Withdrawn - Clinical trials for Ischemic Heart Disease

Lower Leg Remote Ischemic Preconditioning in Elective Percutaneous Coronary Intervention (PCI)

REMOTE
Start date: December 2010
Phase: Phase 0
Study type: Observational

The purpose of this study is to investigate if remote ischemic preconditioning by combining limb ischaemia with electric muscle stimulation of the ischemic muscle provokes better results in preconditioning the human heart than limb ischaemia alone does.

NCT ID: NCT01354678 Terminated - Heart Failure Clinical Trials

Intramyocardial Multiple Precision Injection of Bone Marrow Mononuclear Cells in Myocardial Ischemia

IMPI
Start date: May 2011
Phase: Phase 1
Study type: Interventional

Randomised placebo-controlled study of efficiency and safety of bone marrow mononuclear cells transplantation by intramyocardial multiple precision injection in ischemic heart failure patients.